Abstract:Background aims: Adoptive cellular therapy with immune effector cells (IECs) has shown promising efficacy against some neoplastic diseases as well as potential in immune regulation. Both inherent variability in starting material and variations in cell composition produced by the manufacturing process must be thoroughly evaluated with a validated method established to quantify viable lymphocyte subtypes. Currently, commercialized immunophenotyping methods determine cell viability with significant errors in thawed products since they do not include any viability staining. We hereby report on the validation of a flow cytometry-based method for quantifying viable lymphocyte immunophenotypes in fresh and cryopreserved hematopoietic cellular products. Methods: Using fresh or frozen cellular products and stabilized blood, we report on the validation parameters accuracy, uncertainty, precision, sensitivity, robustness and contamination between samples for quantification of viable CD3+, CD4+ T cells, CD8+ T cells, CD3-CD56+CD16+/- NK cells, CD19+ B cells and CD14+ monocytes of relevance to fresh and cryopreserved hematopoietic cellular products using the Cytomics FC500 cytometer (Beckman Coulter). Results: The acceptance criteria set in the validation plan were all met. The method is able to accommodate the variability in absolute numbers of cells in starting materials collected or cryopreserved from patients or healthy donors (uncertainty of ≤20% at three different concentrations), stability over time (compliance over 3 years during regular inter-laboratory comparisons) and confidence in meaningful changes during cell processing and manufacturing (intra-assay and intermediate precision of 10% coefficient of variation). Furthermore, the method can accurately report on the efficacy of cell depletion since the lower limit of quantification was established (CD3+, CD4+ and CD8+ cells at 9, 8 and 8 cells/µL, respectively). The method complies with Foundation for the Accreditation of Cellular Therapy (FACT) standards for IEC, FACT-Joint Accreditation Committee of ISCT-EBMT (JACIE) hematopoietic cell therapy standards, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Q2(R1) and International Organization for Standardization 15189 standards. Furthermore, it complies with Ligand Binding Assay Bioanalytical Focus Group/American Association of Pharmaceutical Scientists, International Council for Standardization of Hematology/International Clinical Cytometry Society and European Bioanalysis Forum recommendations for validating such methods. Conclusions: The implications of this effort include standardization of viable cell immunophenotyping of starting material for cell manufacturing, cell selection and in-process quality controls or dosing of IECs. This method also complies with all relevant standards, particularly FACT-JACIE standards, in terms of enumerating and reporting on the viability of the "clinically relevant cell populations."

Label‐Free Cell Viability Assay and Enrichment of Cryopreserved Cells Using Microfluidic Cytometry and On‐Demand Sorting

Improved Strategy for Jet-in-air Cell Sorting With High Purity, Yield, Viability and Genome Stability

Assessment and comparison of viability assays for cellular products

An easy and reliable whole blood freezing method for flow cytometry immuno-phenotyping and functional analyses

Label-Free and Noninvasive Single-Cell Characterization for the Viscoelastic Properties of Cryopreserved Human Red Blood Cells Using a Dielectrophoresis-On-a-Chip Approach

Cryopreservation of peripheral blood mononuclear cells for use in proliferation assays: First step towards potency assays

Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry

A Microfluidic Approach for Cryoprotectant Screening: Preliminary Validation with Human Red Blood Cells.

A rapid microfluidic technique for integrated viability determination of adherent single cells

[Influence of Cryopreservation on Human Peripheral Blood Mononuclear Cell Immunocompetence]

The impact of cryopreservation on cytokine secretion and polyfunctionality in human PBMCs: a comparative study

CryoSCAPE: Scalable Immune Profiling Using Cryopreserved Whole Blood for Multi-omic Single Cell and Functional Assays

Improving Reliability of Immunological Assays by Defining Minimal Criteria for Cell Fitness

Isolating Human Peripheral Blood Mononuclear Cells from Buffy Coats via High Throughput Immunomagnetic Bead Separation

Standardization of cryopreserved peripheral blood mononuclear cells through a resting process for clinical immunomonitoring--Development of an algorithm.

On-chip Loading and Unloading of Cryoprotectants Facilitate Cell Cryopreservation by Rapid Freezing

Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products

A-098 Preliminary Tests of Cell Viability, Proteins and mRNA after Freezing PBMC for the Study of Chronic and Acute Lymphoproliferative Leukemias

Acoustic Droplet Vitrification Method for High-Efficiency Preservation of Rare Cells

Understanding the freezing responses of T cells and other subsets of human peripheral blood mononuclear cells using DSMO-free cryoprotectants

Optimization of Blood Handling and Peripheral Blood Mononuclear Cell Cryopreservation of Low Cell Number Samples